MX2021009757A - Formulacion de anestesico local de duracion prolongada. - Google Patents

Formulacion de anestesico local de duracion prolongada.

Info

Publication number
MX2021009757A
MX2021009757A MX2021009757A MX2021009757A MX2021009757A MX 2021009757 A MX2021009757 A MX 2021009757A MX 2021009757 A MX2021009757 A MX 2021009757A MX 2021009757 A MX2021009757 A MX 2021009757A MX 2021009757 A MX2021009757 A MX 2021009757A
Authority
MX
Mexico
Prior art keywords
local anesthetic
duration local
extended duration
long duration
anesthetic formulation
Prior art date
Application number
MX2021009757A
Other languages
English (en)
Inventor
Jeremy Poulsen
Louis Stanfield
Lawrence Volz
Original Assignee
Ventis Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventis Pharma filed Critical Ventis Pharma
Publication of MX2021009757A publication Critical patent/MX2021009757A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
    • A61J1/2093—Containers having several compartments for products to be mixed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
    • B65D81/3261—Flexible containers having several compartments
    • B65D81/3266—Flexible containers having several compartments separated by a common rupturable seal, a clip or other removable fastening device
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mechanical Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Un anestésico de duración prolongada incluye un anestésico local de corta duración en una solución diluida y un anestésico local de larga duración; el anestésico local de larga duración es mantenido en una forma de polvo hasta el momento de la administración; las cantidades previamente medidas de la solución diluida y el anestésico local de larga duración en polvo en un kit permiten la rápida preparación de una solución con las concentraciones deseadas del anestésico local de corta duración y el anestésico local de larga duración al momento de la administración.
MX2021009757A 2015-12-04 2016-12-02 Formulacion de anestesico local de duracion prolongada. MX2021009757A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/960,214 US10117847B2 (en) 2015-12-04 2015-12-04 Extended duration local anesthetic formulation
PCT/US2016/064782 WO2017096273A1 (en) 2015-12-04 2016-12-02 Extended duration local anesthetic formulation

Publications (1)

Publication Number Publication Date
MX2021009757A true MX2021009757A (es) 2022-05-17

Family

ID=58797907

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021009757A MX2021009757A (es) 2015-12-04 2016-12-02 Formulacion de anestesico local de duracion prolongada.
MX2018006815A MX2018006815A (es) 2015-12-04 2016-12-02 Formulación de anestésico lócal de duración prolongada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018006815A MX2018006815A (es) 2015-12-04 2016-12-02 Formulación de anestésico lócal de duración prolongada.

Country Status (15)

Country Link
US (4) US10117847B2 (es)
EP (2) EP3383370B1 (es)
JP (2) JP6625761B2 (es)
KR (2) KR101965131B1 (es)
CN (2) CN113143852B (es)
AU (2) AU2016362992B2 (es)
BR (2) BR122020022702B1 (es)
CA (1) CA3007352C (es)
ES (1) ES2862184T3 (es)
HR (1) HRP20210658T1 (es)
IL (2) IL264539B2 (es)
MX (2) MX2021009757A (es)
NZ (2) NZ754276A (es)
PT (1) PT3383370T (es)
WO (1) WO2017096273A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10117847B2 (en) * 2015-12-04 2018-11-06 Ventis Pharma Extended duration local anesthetic formulation
IT201800002292A1 (it) * 2018-02-01 2019-08-01 Renato Cappelletti Nuove formulazioni di miscele anestetiche per anestesia locale, a bassissima concentrazione, da utilizzare fredde con idoneo packaging
US11219629B2 (en) * 2019-10-17 2022-01-11 Hooman M. MELAMED Anesthetic pharmaceutical composition, system and method
CN114948953A (zh) * 2021-06-29 2022-08-30 四川大学华西医院 一种杂原子取代芳香类化合物及其盐的用途
WO2023154293A1 (en) * 2022-02-08 2023-08-17 Saint Cyr Michael Hector Anesthetic formulations and methods
US11890422B2 (en) * 2022-05-05 2024-02-06 Pfof Llc Anesthetic nerve block and method
US12070454B1 (en) * 2022-05-05 2024-08-27 Pfof Llc Anesthetic nerve block and method

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5261903A (en) * 1988-04-11 1993-11-16 M.D. Inc. Composite anesthetic article and method of use
US5176634A (en) 1990-08-02 1993-01-05 Mcgaw, Inc. Flexible multiple compartment drug container
US5141460A (en) 1991-08-20 1992-08-25 Jaskie James E Method of making a field emission electron source employing a diamond coating
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US5585398A (en) 1994-07-15 1996-12-17 Ernst; Amy A. Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
HUP9700322A3 (en) * 1995-06-09 2001-03-28 Euro Celtique Sa Formulations and methods for providing prolonged local anesthesia
CN1069826C (zh) 1997-04-25 2001-08-22 浙江省中医院 盐酸丁卡因冻干粉针剂
US6432986B2 (en) 1997-07-21 2002-08-13 Bruce H. Levin Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches
US5954703A (en) * 1997-10-31 1999-09-21 Dusa Pharmaceuticals, Inc. Method and apparatus for applying 5-aminolevulinic acid
US6708822B1 (en) * 1999-11-30 2004-03-23 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
WO2004009064A1 (de) * 2002-07-19 2004-01-29 Mestex Ag Verwendung von neurotoxischen substanzen für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
JP2006513224A (ja) * 2002-12-20 2006-04-20 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ エステル局所麻酔薬の組み合わせ
US20040142968A1 (en) * 2003-01-17 2004-07-22 Donald Price Method and kit for treating lower bowel pain
EP2839830B1 (en) 2005-01-14 2019-05-15 Urigen, Inc. Kits and compositions for treating lower urinary tract disorders
CA2704928A1 (en) 2007-11-06 2009-05-14 Stuart L. Weg Anesthetic composition, formulation and method of use
BR112013011594A2 (pt) * 2010-11-09 2016-08-09 Jie Zhang sistemas de combinação de lâminas e líquidos para a liberação de medicamento dérmico
EP2537541A1 (en) 2011-06-23 2012-12-26 Metpro AB Container and connector for providing a medical solution
US9186299B1 (en) 2012-03-23 2015-11-17 Clark Levi Topical pharmaceutical compounds and methods
JP2012143629A (ja) * 2012-05-07 2012-08-02 Nipro Corp 医療用複室容器
BR112015018047A8 (pt) 2013-01-28 2019-11-05 Urigen Pharmaceuticals Inc método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas
NZ710890A (en) * 2013-03-15 2016-11-25 Childrens Medical Ct Corp Neosaxitoxin combination formulations for prolonged local anesthesia
WO2015126942A1 (en) * 2014-02-18 2015-08-27 Glenn Abrahmsohn Compositions and methods for pain relief without numbness
US10117847B2 (en) * 2015-12-04 2018-11-06 Ventis Pharma Extended duration local anesthetic formulation

Also Published As

Publication number Publication date
IL264539A (en) 2019-02-28
KR101965131B1 (ko) 2019-04-03
HRP20210658T1 (hr) 2021-09-03
NZ743787A (en) 2019-07-26
CN108883065A (zh) 2018-11-23
EP3383370A1 (en) 2018-10-10
US20230233504A1 (en) 2023-07-27
AU2016362992B2 (en) 2019-08-01
PT3383370T (pt) 2021-04-06
US11154528B2 (en) 2021-10-26
IL264539B1 (en) 2024-02-01
IL264539B2 (en) 2024-06-01
US20190029988A1 (en) 2019-01-31
BR112018011307A2 (pt) 2018-11-27
JP6898980B2 (ja) 2021-07-07
US10117847B2 (en) 2018-11-06
KR20180082612A (ko) 2018-07-18
US11564902B2 (en) 2023-01-31
JP2019505534A (ja) 2019-02-28
AU2016362992A1 (en) 2018-07-12
WO2017096273A1 (en) 2017-06-08
EP3383370A4 (en) 2018-12-26
JP6625761B2 (ja) 2019-12-25
AU2019257386A1 (en) 2019-11-14
ES2862184T3 (es) 2021-10-07
CA3007352C (en) 2023-10-10
AU2019257386B2 (en) 2021-11-25
NZ754276A (en) 2023-05-26
US20200405679A1 (en) 2020-12-31
US20170157082A1 (en) 2017-06-08
IL259778A (en) 2018-07-31
EP3383370B1 (en) 2021-02-03
EP3845217A1 (en) 2021-07-07
BR122020022702B1 (pt) 2023-12-19
MX2018006815A (es) 2019-05-06
JP2020040986A (ja) 2020-03-19
IL259778B (en) 2019-03-31
KR102378452B1 (ko) 2022-03-23
CA3007352A1 (en) 2017-06-08
KR20190035965A (ko) 2019-04-03
CN113143852B (zh) 2023-05-09
BR112018011307B1 (pt) 2023-12-19
CN108883065B (zh) 2021-04-06
CN113143852A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
MX2021009757A (es) Formulacion de anestesico local de duracion prolongada.
MX2021006912A (es) Composiciones para la administracion de agentes terapeuticos y metodos de uso y fabricacion de las mismas.
NZ712350A (en) Abiraterone acetate formulation
MX2021015789A (es) Reduccion de la viscosidad de formulaciones farmaceuticas.
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
EP3686184A3 (en) Ionizable compounds and compositions and uses thereof
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
MX2021009377A (es) Formulaciones de espuma y aparatos para su suministro.
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
MY177927A (en) Anti-sensitive composition for tooth
MX2016014230A (es) Alimentos, sistemas, metodos y kits para proporcionar reemplazo de electrolitos.
AR095398A1 (es) Formulaciones con oxidación reducida
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
CY1122797T1 (el) Μεθοδος παρασκευης συνθεσεων ξηρας σκονης για εισπνοη
BR112016013577A2 (pt) Proteínas de fusão, seu uso e composição farmacêutica
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
PH12018502139A1 (en) Phosphaplatin liquid formulations
BR112015025781A2 (pt) composição farmacêutica para uso inalatório e kit para a administração de um fármaco como um pó inalatório
MX2017000989A (es) Aditivo para sedimentar de forma mineral composiciones acuosas de mortero.
MY195763A (en) A Herbicidal Composition and Process Thereof
EA201692456A1 (ru) Способ получения составов для ингаляции
PH12019501049A1 (en) Pharmaceutical composition containing palonosetron as active ingredient
EP3675767C0 (de) Nachlauffreie spritze, insbesondere zur verabreichung dentaler pastöser zusammensetzungen, und kit